Introduction

This page provides a comprehensive analysis of the known insider trading history of Andrew R Allen. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Andrew R Allen has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:GRTS / Gritstone bio, Inc. PRESIDENT AND CEO, Director 985,360
US:SRRA / Sierra Oncology Inc Director, 10% Owner 0
US:TCRR / Tcr2 Therapeutics Inc Director 12,100
US:EPZM / Epizyme Inc Director 40,559
US:CLVS / Clovis Oncology Inc See Remarks 35,000
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Andrew R Allen. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Trading History

This table shows the complete list of insider trades made by Andrew R Allen as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2024-06-26 2024-06-24 4 GRTS Gritstone bio, Inc.
Common Stock
G - Gift -325,000 985,360 -24.80
2024-06-26 2024-06-24 4 GRTS Gritstone bio, Inc.
Common Stock
G - Gift -325,000 985,360 -24.80
2024-05-17 2024-05-16 4 GRTS Gritstone bio, Inc.
Common Stock
S - Sale -24,263 985,360 -2.40 0.75 -18,156 737,345
2024-05-17 2024-05-15 4 GRTS Gritstone bio, Inc.
Common Stock
A - Award 47,873 1,009,623 4.98
2024-02-05 2024-02-01 4 GRTS Gritstone bio, Inc.
Common Stock
A - Award 105,000 899,345 13.22
2023-02-06 2023-02-02 4 GRTS Gritstone bio, Inc.
Common Stock
A - Award 738,550 856,750 624.83
2022-07-01 2022-07-01 4 SRRA Sierra Oncology, Inc.
Common Stock
D - Sale to Issuer -1,650 0 -100.00 55.00 -90,750
2022-04-20 2022-01-31 4 GRTS Gritstone bio, Inc.
Stock Option (Right to Buy)
A - Award 410,000 410,000
2022-04-20 2022-01-31 4 GRTS Gritstone bio, Inc.
Common Stock
A - Award 70,000 118,200 145.23
2021-12-10 2021-12-09 4 TCRR TCR2 THERAPEUTICS INC.
Stock Option (Right to Buy)
A - Award 12,100 12,100
2021-11-19 2021-01-07 4 GRTS Gritstone bio, Inc.
Common Stock
A - Award 48,200 48,200
2021-06-15 2021-06-11 4 EPZM Epizyme, Inc.
Stock Option (Right to Buy)
A - Award 40,559 40,559
2021-06-15 2021-06-11 4 EPZM Epizyme, Inc.
Common Stock, par value $0.0001
A - Award 8,060 20,560 64.48
2021-06-09 2021-06-08 4 SRRA Sierra Oncology, Inc.
Stock Option (Right To Buy)
A - Award 6,000 6,000
2021-03-10 2021-03-08 4 GRTS Gritstone Oncology, Inc.
Stock Option (Right to Buy)
A - Award 290,000 290,000
2020-12-11 2020-12-10 4 TCRR TCR2 THERAPEUTICS INC.
Stock Option (Right to Buy)
A - Award 12,100 12,100
2020-06-10 2020-06-09 4 SRRA Sierra Oncology, Inc.
Stock Option (right to buy)
A - Award 12,030 12,030
2020-06-02 2020-05-29 4 EPZM Epizyme, Inc.
Stock Option (Right to Buy)
A - Award 14,013 14,013
2020-03-18 2020-03-16 4 EPZM Epizyme, Inc.
Stock Option (Right to Buy)
M - Exercise -12,500 0 -100.00
2020-03-18 2020-03-16 4 EPZM Epizyme, Inc.
Common Stock
M - Exercise 12,500 12,500 9.33 116,625 116,625
2020-02-27 2020-02-25 4 GRTS Gritstone Oncology, Inc.
Stock Option (Right to Buy)
A - Award 275,000 275,000
2019-12-20 2019-12-19 4 TCRR TCR2 THERAPEUTICS INC.
Stock Option (Right to Buy)
A - Award -5,000 5,000 -50.00
2019-06-12 2019-06-11 4 SRRA Sierra Oncology, Inc.
Stock Option (right to buy)
A - Award 30,000 30,000
2019-06-07 2019-05-31 4 EPZM Epizyme, Inc.
Stock Option (Right to Buy)
A - Award 17,633 17,633
2019-04-12 2019-04-11 4 TCRR TCR2 THERAPEUTICS INC.
Stock Option (Right to Buy)
A - Award 6,270 6,270
2019-03-14 2019-02-13 4 GRTS Gritstone Oncology, Inc.
Stock Option (Right to Buy)
A - Award 180,000 180,000
2018-12-11 2018-12-10 4 SRRA Sierra Oncology, Inc.
Common Stock
P - Purchase 66,000 66,000 1.64 108,240 108,240
2018-09-27 3 GRTS Gritstone Oncology, Inc.
Common Stock
2,898,550
2018-09-27 3 GRTS Gritstone Oncology, Inc.
Common Stock
2,898,550
2018-09-27 3 GRTS Gritstone Oncology, Inc.
Common Stock
2,898,550
2018-06-14 2018-06-12 4 SRRA Sierra Oncology, Inc.
Stock Option (right to buy)
A - Award 25,000 25,000
2018-05-31 2018-05-18 4 EPZM Epizyme, Inc.
Stock Option (Right to Buy)
A - Award 12,500 12,500
2017-11-13 2017-11-10 4 SRRA Sierra Oncology, Inc.
Stock Option (Right to Buy)
A - Award 50,000 50,000
2017-10-25 3 SRRA Sierra Oncology, Inc.
No securities beneficially owned.
0
2017-06-26 2017-06-22 4 EPZM Epizyme, Inc.
Stock Option (Right to Buy)
A - Award 12,500 12,500
2016-05-23 2016-05-19 4 EPZM Epizyme, Inc.
Stock Option (Right to Buy)
A - Award 12,500 12,500
2015-07-10 2015-07-08 4 EPZM Epizyme, Inc.
Stock Option (Right to Buy)
A - Award 7,333 7,333
2015-03-04 2015-03-02 4 CLVS Clovis Oncology, Inc.
Stock Option (right to buy)
A - Award 35,000 35,000
2015-01-21 2015-01-16 4/A CLVS Clovis Oncology, Inc.
Common Stock
S - Sale X -49,176 101,919 -32.55 66.26 -3,258,171 6,752,674
2015-01-21 2015-01-16 4/A CLVS Clovis Oncology, Inc.
Common Stock
S - Sale X -30,524 151,095 -16.81 65.27 -1,992,225 9,861,593
2015-01-21 2015-01-15 4/A CLVS Clovis Oncology, Inc.
Common Stock
S - Sale X -300 181,619 -0.16 65.00 -19,500 11,805,235
2015-01-20 2015-01-16 4 CLVS Clovis Oncology, Inc.
Common Stock
S - Sale X -49,176 101,919 -32.55 65.88 -3,239,567 6,714,118
2015-01-20 2015-01-16 4 CLVS Clovis Oncology, Inc.
Common Stock
S - Sale X -30,524 151,095 -16.81 65.27 -1,992,225 9,861,593
2015-01-20 2015-01-15 4 CLVS Clovis Oncology, Inc.
Common Stock
S - Sale X -300 181,619 -0.16 65.00 -19,500 11,805,235
2014-06-11 2014-06-09 4 EPZM Epizyme, Inc.
Stock Option (Right to Buy)
A - Award 17,666 17,666
2014-06-11 3 EPZM Epizyme, Inc.
No securities are beneficially owned
0
2014-01-14 2014-01-10 4 CLVS Clovis Oncology, Inc.
Stock Option (right to buy)
A - Award 70,000 70,000
2013-06-07 2013-06-05 4 CLVS Clovis Oncology, Inc.
Common Stock
S - Sale -2,600 0 -100.00 70.72 -183,872
2013-06-07 2013-06-05 4 CLVS Clovis Oncology, Inc.
Common Stock
S - Sale -5,800 2,600 -69.05 70.06 -406,348 182,156
2013-06-07 2013-06-05 4 CLVS Clovis Oncology, Inc.
Common Stock
S - Sale -2,500 8,400 -22.94 68.84 -172,100 578,256
2013-06-07 2013-06-05 4 CLVS Clovis Oncology, Inc.
Common Stock
S - Sale -6,494 10,900 -37.33 67.65 -439,319 737,385
2013-06-07 2013-06-05 4 CLVS Clovis Oncology, Inc.
Common Stock
S - Sale -4,500 17,394 -20.55 66.89 -301,005 1,163,485
2013-06-07 2013-06-05 4 CLVS Clovis Oncology, Inc.
Common Stock
S - Sale -700 21,894 -3.10 65.77 -46,039 1,439,968
2013-03-04 2013-03-01 4 CLVS Clovis Oncology, Inc.
Stock Option (right to buy)
A - Award 75,000 75,000
2013-02-15 2012-12-11 5 CLVS Clovis Oncology, Inc.
Common Stock
G - Gift 10,000 204,513 5.14
2013-02-15 2012-12-11 5 CLVS Clovis Oncology, Inc.
Common Stock
G - Gift -3,077 194,513 -1.56
2013-02-15 2012-12-11 5 CLVS Clovis Oncology, Inc.
Common Stock
G - Gift -10,000 197,590 -4.82
2013-02-15 2012-01-18 5 CLVS Clovis Oncology, Inc.
Common Stock
G - Gift 12,594 207,590 6.46
2013-02-15 2012-01-18 5 CLVS Clovis Oncology, Inc.
Common Stock
G - Gift -1,562 194,996 -0.79
2013-02-15 2012-01-18 5 CLVS Clovis Oncology, Inc.
Common Stock
G - Gift -13,852 196,558 -6.58
2013-02-15 2012-01-18 5 CLVS Clovis Oncology, Inc.
Common Stock
G - Gift -12,594 210,410 -5.65
2012-03-05 2012-03-01 4 CLVS Clovis Oncology, Inc.
Stock Option (right to buy)
A - Award 50,000 50,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)